| Identification | Back Directory | [Name]
(2R,3R,4S,5S,6R)-4-Amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxy-cyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol | [CAS]
34493-98-6 | [Synonyms]
ibekacin
DIBEKACIN
Aids070753
Aids-070753
Brn 1441606
4)]-2-deoxy-
Dibekacin USP/EP/BP
4'-Dideoxykanamycin B
Dibekacin（Dideoxykanamycin B）
D-StreptaMine,O-3-aMino-3-deoxy-a-D-glucopyranosyl-(1®
6)-O-[2,6-diaMino-2,3,4,6-tetradeoxy-a-D-erythro-hexopyranosyl-(1®
6-O-(3-Amino-3-deoxy-α-D-glucopyranosyl)-4-O-(2,6-diamino-2,3,4,6-tetradeoxy-α-D-erythro-hexopyranosyl)-2-deoxy-D-streptamine
O-3-AMino-3-deoxy-α-D-glucopyranosyl-(1→6)-O-[2,6-diaMino-2,3,4,6-tetradeoxy-α-D-erythro-hexopyranosyl-(1→4)]-2-deoxy-D-streptaMine
D-Streptamine, O-3-amino-3-deoxy-α-D-glucopyranosyl-(1→6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-α-D-erythro-hexopyranosyl-(1→4)]-2-deoxy-
D-Streptamine, o-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranosyl)-(1-4)-2-deoxy-
(2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
(2R,3R,4S,5S,6R)-4-Amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxy-cyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
(2S,3R,4S,5S,6R)-4-amino-2-(((1S,2S,3R,4S,6R)-4,6-diamino-3-(((2R,3R,6S)-3-amino-6-(aminomethyl)tetrahydro-2H-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol | [EINECS(EC#)]
252-064-6 | [Molecular Formula]
C18H37N5O8 | [MDL Number]
MFCD00210275 | [MOL File]
34493-98-6.mol | [Molecular Weight]
451.52 |
| Chemical Properties | Back Directory | [alpha ]
D20 +132° (c = 0.65) | [Boiling point ]
559.28°C (rough estimate) | [density ]
1.3132 (rough estimate) | [refractive index ]
1.7600 (estimate) | [pka]
13.07±0.70(Predicted) | [CAS DataBase Reference]
34493-98-6 |
| Hazard Information | Back Directory | [Definition]
ChEBI: A kanamycin that is kanamycin B lacking the 3- and 4-hydroxy groups on the 2,6-diaminosugar ring. | [Description]
Dibekacin was synthesized in 1967 by Umezawa et al. by the removal of the 3 - and 4 -hydroxyl groups of kanamycin B. Studies by the same workers on the mechanisms of bacterial resistance to kanamycin-group antibiotics preceded the discovery. Dibekacin shows excellent activity, as expected, against a variety of bacteria, including kanamycin-resistant strains. It shows higher activity than kanamycin against Pseudomonas aeruginosa, Proteus, and other pathogens. | [Originator]
Panimycin,Meiji Seika,Meiji Seika,1975 | [Uses]
Dideoxykanamycin B is an antibacterial compound. | [Manufacturing Process]
Penta-N-benzyloxycarbonyl-2"-O-benzylsulfonyl-3',4'-dideoxy-3'-enokanamycin B (61 mg) was dissolved in about 18 ml of liquid ammonia at -
50°C, followed by addition of about 120 mg of metal sodium. The mixture was
gently stirred at -50°C for 1 hour, followed by addition of methanol to
consume up the excess of the metal sodium. The reaction mixture was
allowed to slowly raise up to ambient temperature while permitting the
ammonia to evaporate. The residue so obtained was dissolved in water, and
the aqueous solution was admixed with 4 ml of a cation-exchange resin,
Dowex 50WX2 (H cycle) (a product of Dow Chemical Co., USA) under stirring.
The admixture comprising the resin was placed on the top of a column of 3,5
ml of the same resin. Dowex 50WX2, and the whole resin column was well
washed with water and then eluted using 1 M aqueous ammonia as the
developing solvent. The eluate was collected in fractions, and such fractions
which gave positive reaction with ninhydrin were combined together and
concentrated to dryness, affording 3',4'-dideoxy-3'-eno-kanamycin B in the
form of its monocarbonate. The yield was 23,8 mg (97%).
The product (12.1 mg) obtained in the above step was dissolved in 0.3 ml of
water, to which was then added a catalytic quantity (about 5 mg) of platinum
oxide. Hydrogenation was made with hydrogen gas at a pressure of 3.5
kg/cm2 for 1? hours. The reaction solution was filtered to remove the
catalyst, and the filtrate was concentrated to dryness, giving the desired
product 3',4'-dideoxykanamycin B in the form of its monocarbonate. The yield
was 11.5 mg (95%). [α]D25 +110° (c 1, water). The overall yield of 3',4'-
dideoxykanamycin B based on the starting kanamycin B was 57%. | [Therapeutic Function]
Antibacterial | [Antimicrobial activity]
3′,4′-Dideoxy kanamycin B. A semisynthetic aminoglycoside
closely related to the natural compound tobramycin (3′-deoxy
kanamycin B). Supplied as the sulfate.
It is active against staphylococci including methicillinresistant
strains, a wide range of enterobacteria, Acinetobacter
and Pseudomonas spp. It is also active against M. tuberculosis
and the M. avium complex (MICs 4–16 mg/L). It exhibits
the usual aminoglycoside properties of bactericidal activity
at concentrations close to the MIC and bactericidal synergy
with selected β-lactam antibiotics.
Absence of hydroxyl groups present in the parent kanamycin
B renders dibekacin resistant to phosphorylation
by APH(3′). It is also resistant to some forms of ANT(4′).
However, the type of this enzyme, ANT(4′), found in
some Gram-positive organisms modifies dibekacin at the
2″-hydroxyl group; nevertheless dibekacin has much greater
activity than tobramycin against organisms that produce the
enzyme.
A 1 mg/kg intravenous bolus dose achieves a peak plasma
concentration of around 5 mg/L. The plasma half-life is
2.3 h. Protein binding is 3–12%. It is eliminated principally
by the renal route, 75–80% of the dose appearing in
the urine in the first 24 h. Elimination is inversely related to
renal function. In patients maintained on chronic hemodialysis,
the half-life rises to 54 h between dialyses and falls to
6–7 h on dialysis.
Toxic effects are those typical of aminoglycosides with a
frequency similar to or less than those of gentamicin.
It is used for severe infections caused by susceptible microorganisms,
especially those resistant to established aminoglycosides,
but availability is limited. | [Synthesis]
Dibekacin is synthesized from
kanamycin B by the application of the Tipson-
Cohen deoxygenation method after selective Nand
O-protections . A modified synthetic
route via the 3_x0002_,4_x0002_-epoxy compound has given a
high yield of more than 40 % on an industrial
scale . |
| Safety Data | Back Directory | [Safety Profile]
Poison by
intraperitoneal, subcutaneous, intramuscular,
and intravenous routes. Moderately toxic by
ingestion. Experimental teratogenic and
reproductive effects. An antibacterial agent.
When heated to decomposition it emits
toxic fumes of NOx. | [Toxicity]
LD50 in mice (mg/kg): 61.0-68.0 i.v., 373.0-380.0 i.m. (Komiya) |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
T&W GROUP
|
| Tel: |
021-61551611 13296011611 |
| Website: |
www.trustwe.com/ |
|